Former FDA Commissioners Criticized Agency Staffing Cuts

The officials warned that recent personnel reductions have compromised the agency's institutional knowledge.

Updated on Oct. 14, 2026 in People

Former FDA Commissioners Criticized Agency Staffing Cuts

Live Poll

Do you trust that federal health agencies are making decisions free from political influence?

Three former FDA commissioners voiced concerns regarding the loss of institutional memory following the layoffs of 3,500 agency workers. The job cuts were implemented through the Department of Government Efficiency, prompting the FDA to begin a rehiring process.

Why it matters

Former officials argue that restoring the workforce is essential to protect the agency from political interference and rebuild critical expertise. They cautioned that the recovery process will likely take years to complete.

The agency recently saw 3,500 staff positions eliminated through the Department of Government Efficiency. While the FDA has initiated a rehiring effort, the full extent of the institutional knowledge loss remains under investigation.

The players

Marty Makary

He is a former FDA commissioner who resigned from his post in May 2026.

Heidi Overton

She is the nominee to replace Marty Makary as the FDA commissioner and currently awaits a Senate confirmation vote.

Kyle Diamantas

He currently serves as the acting FDA commissioner.

Grace Graham

She serves as the FDA policy lead.

Vinay Prasad

He is a former top drug and device regulator who previously departed the FDA.

The details

At a panel held in Boston, former regulators including Marty Makary, Vinay Prasad, and Tracy Beth Høeg discussed the impact of the staff reductions. The agency previously gained attention for adding safety warnings to mRNA Covid-19 vaccines in 2025, a period preceding these leadership changes.

May 2026: Former FDA Commissioner Marty Makary resigned from his position.
2025: The FDA added safety warnings to mRNA Covid-19 vaccines regarding heart inflammation.
October 14, 2026: Three former FDA commissioners held a panel at the STAT Summit in Boston.

Market Landscape

This staffing restructuring follows the federal mandate of the Department of Government Efficiency initiative. It positions the agency in a period of transition as it attempts to reconcile administrative mandates with the necessity of maintaining specialized regulatory oversight.

The potential for long-term delays in regulatory oversight may impact the approval timelines for new drugs and medical devices. Patients and consumers should monitor updates from the FDA regarding how these staffing gaps could influence product safety or availability.

The takeaway

Restoring institutional knowledge in a federal agency is a multi-year challenge that requires stability in leadership and policy. Stakeholders should track the upcoming Senate confirmation of the new commissioner to understand the future regulatory direction of the agency.